Primary cutaneous marginal zone B-cell lymphoma (PCMZL) was linked to aberrant nuclear B-cell lymphoma 10 (BCL10) expression, but not t(11;18)(Q21;q21) translocation

10-18-2006

"Inhibition of apoptosis seems to play an important role in the pathogenesis of marginal zone lymphoma. Apoptosis regulator BCL10 may show aberrant nuclear localization in some aggressive extracutaneous MALT lymphomas, often in association with a MALT1 gene t(11;18)(q21;q21) translocation. The possible occurrence of this association in PCMZL remains insufficiently explored," scientists in Spain reported.

"The aim of this study was to evaluate BCL10 protein expression pattern and its possible relationship to the presence of t(11:18)(q21;q21) and other MALT1 gene abnormalities in PCMZL and to assess their clinical significance. The study included 42 consecutive PCMZL patients diagnosed on the basis of the World Health Organization/European Organization for the Research and Treatment of Cancer classification criteria," explained F. Gallardo and colleagues, Hospital del Mar.

"BCL10 expression was immunohistochemically evaluated in all cases, whereas t(11;18)(q21;q21) reverse transcriptase polymerase chain reaction amplification was performed on 21 samples. In addition, the presence of other MALT1 gene translocations was explored in 26 samples by interphase fluorescence in situ hybridization using a MALT1 locus-specific probe.

"We observed the presence of aberrant nuclear BCL10 expression in a significant number of PCMZL cases (36%, 15/42). This aberrant expression was significantly related to the development of extracutaneous disease. In contrast, neither the t(11;18)(q21;q21) translocation nor other MALT1 gene translocations could be demonstrated. t(11;18)(q21;q21), strongly linked to extracutaneous MALT lymphomas, does not seem to play a role in PCMZL," noted the investigators.

The researchers concluded, "The participation of other MALT1 gene translocations in PCMZL pathogenesis seems also unlikely."

Gallardo and colleagues published their study in Human Pathology (Aberrant nuclear BCL10 expression and lack of t(11;18)(Q21;q21) in primary cutaneous marginal zone B-cell lymphoma. Hum Pathol, 2006;37(7):867-873).

For additional information, contact F. Gallardo, Hospital del Mar, Dept. of Dermatology, IMAS, Passeig Maritim 25-29, E-08003 Barcelona, Spain.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Related Keywords: MALT1, BCL-10, Apoptosis, Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL)
Related Glossary Terms: NHL, Hodgkin Lymphoma
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Intrabone admin of unrelated cord-blood cells lets more leukemia patients undergo transplantation
Sparing leukemia patients from unnecessary chemo
Acute Myeloid Leukemia (AML)
FDA Approves Vidaza Label Expansion
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Australian scientists unravel Leukaemia link
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study
Sparing leukemia patients from unnecessary chemo
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Chronic Myeloid Leukemia (CML)
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Targeted therapies for CML: practical considerations and comparisons
Sparing leukemia patients from unnecessary chemo
Hodgkin Lymphoma
Nerve cancer mutations found
Autologous Stem Cell Transplantation Effective for Relapsed or Refractory Hodgkin’s Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Multiple Myeloma
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
ESAs cut survival by more than half in multiple myeloma
How molecules out of balance lead to human multiple myeloma and other cancers
Myelodysplastic Syndrome (MDS)
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Non-Hodgkin Lymphoma (NHL)
Nerve cancer mutations found
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Ofatumumab Promising in Refractory Follicular Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer